SUMMARY -Hepatic osteodystrophy is a common and frequently untreated complication, manifested as osteoporosis or osteopenia, encountered in the evolution of chronic liver diseases. Th is article provides a narrative review of hepatic osteodystrophy. Th e aim is to revise the prevalence, pathophysiology, diagnosis and management of hepatic osteodystrophy. We searched medical literature via PubMed, Google Scholar, Wiley, Science Direct, and Springer Link using respective keywords to obtain data on low bone mineral density connected to chronic liver diseases. Many studies have reported an increased prevalence of osteoporosis/osteopenia in patients with chronic liver diseases. Th e pathogenesis is multifactorial, involving genetic factors, vitamin defi ciencies, proinfl ammatory cytokines, hypogonadism, hyperbilirubinemia, antiviral therapy, corticosteroid drugs, and lifestyle factors. Th e management of patients should include individualized assessment for fracture risk factors and bone mineral density. Vitamin D and calcium supplementation should be recommended in all patients with chronic liver diseases and osteoporosis. Bisphosphonates are the most effi cient drugs used in the treatment of hepatic osteodystrophy. In the future, it is necessary to defi ne better the management and specifi c treatment of hepatic osteodystrophy for prevention of fragility fractures and to improve the patient quality of life.
Introduction
Alterations of bone metabolism in patients with chronic liver diseases (CLD) represent an important complication that has been in the researchers' focus in recent years. Th is pathology is represented by osteoporosis or osteopenia, and seldom by osteomalacia, that may lead to morbidity (bone pain, skeletal deformities, immobilization, and fragility fractures) 1 . All alterations of bone metabolism that appear in the evolution of CLD are defi ned as hepatic osteodystrophy (HO) 2 .
HO is a common complication of CLD and it involves impairment of bone mineral density (BMD). Th erefore, assessment should be made in patients with CLD in order to preserve their quality of life and predict long-term prognosis 3 . Th ere are many factors that are involved in the etiology of HO but the pathogenesis of this form of secondary osteoporosis is still incompletely understood 2 . Bone disorders may be found in viral, autoimmune or alcoholic CLD, but more frequently in CLD associated with cholestasis such as primary biliary cirrhosis and primary sclerosing cholangitis 4, 5 . Th is article provides an overview of this topic.
Material and Methods
For our narrative review, we searched medical literature using the following databases: PubMed,
Prevalence of Hepatic Osteodystrophy
Physiologically, peak bone density is achieved at around 30 years and then bone is lost at a rate of 0.5%-1% per year. In women, bone loss is accelerated in menopause, especially for 3-5 years of menopause onset. BMD also decreases with age, so the risk of fractures increases dramatically, mainly after the age of 60. Th us, osteoporotic fractures are known to impair the quality of life and daily activities, cause chronic pain and social isolation, increase the usage of pain killers and increase mortality 6 . Th e prevalence of osteoporosis in patients with CLD ranges from 3% to 48% [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] , whereas the prevalence of osteopenia varies between 20% and 68%, depending on the etiology, pathogenesis and size of patient samples 8-10, [13] [14] [15] [16] [17] [18] . Th e prevalence of fractures in patients with HO is between 5.3% in patients with chronic viral hepatitis or primary biliary cirrhosis and 23.7% in patients before orthotopic liver transplantation (Table 1) 8, 13 . Most of these studies used dual energy x-ray absorptiometry (DXA) to assess BMD (at lumbar spine and femoral neck) and to diagnose osteopenia and osteoporosis (except for the fi rst study in Table 1 , where spinal quantitative computed tomography and single photon absorptiometry were used). Th e etiology of HO in these studies varied from viral hepatitis and viral cirrhosis to primary biliary cirrhosis and end stage liver disease.
Pathogenesis of Hepatic Osteodystrophy
In pathologic conditions, BMD is reduced as a result of imbalance between bone formation and bone resorption. Some studies focused on bone resorption, especially in postmenopausal women, whereas other studies have reported decreased bone formation 19, 20 . Th e risk of fractures in patients with CLD is determined by BMD, trabecular architecture and geometry, bone turnover, and risk factors 2 . Many risk factors for HO have been reported such as genetic factors, vitamin D defi ciency and calcium disorders, vitamin K defi ciency, insulin-like growth factor 1 (IGF-1) deficiency, hyperbilirubinemia, hypogonadism, inadequate activity of the system of receptor activator of nuclear factor kappa B ligand/osteoprotegerin (RANKL/ OPG), medication, fi bronectin, hiperhomocysteinemia, leptin, and lifestyle (Table 2) 2 .
Genetic factors
Genetic polymorphisms of vitamin D receptor and genetic polymorphisms of proteins that are implicated in vitamin D synthesis have been reported to play a role in CLD bone disorders, especially in primary biliary cirrhosis 21 . Other genetic factors have also been reported to be involved in bone loss in patients with primary biliary cirrhosis, such as polymorphisms of collagen α 1 (I) gene, IGF-1, interleukin 1 (IL-1) receptor antagonist (IL1RA), and estrogen receptor α (ERα) 21, 22 . Data on vitamin D receptor and collagen α 1 (I) gene are discordant and no correlation has been found with an increased risk of osteoporosis for IL1RA or IGF-1 in the presence of ERα polymorphisms 23 . Additionally, other known factors for osteoporosis may increase the risk of HO development. Female gender is a common risk factor for osteoporosis, including CLD osteoporosis. Th ere has been reported that 21% of women aged 50-84 have osteoporosis (more than 12 million women from countries such as Germany, France, Italy, Spain and United Kingdom) 24 . White and Asian races are those with lower BMD than other ethnic groups 25 . Family risk of hip fracture has also been reported to be associated with the occurrence of osteoporosis and osteoporotic fractures in women, according to the study by Pinheiro et al. 26 .
Vitamin D defi ciency and calcium disorders
Previtamin D 3 (the fi rst form of vitamin D which comes from the cholesterol metabolite 7-dehydrocholesterol under the eff ect of ultraviolet-B radiation) is transformed into vitamin D 3 in the skin. Only a very . Th e role of this active form is to increase calcium resorption in the gastrointestinal tract, osteoclast activity (bone resorption) and osteoblast activity (bone mineralization) 27 . In the study by Arteh et al., vitamin D defi ciency has been reported in most patients with CLD (92%), and one-third of patients presented severe vitamin D defi ciency 28 . Vitamin D defi ciency in CLD is caused by malnutrition, limited sun exposure, intestinal malabsorption, and decreasing skin synthesis (especially in patients with jaundice) 2 . Nevertheless, the relationship between vitamin D and CLD remains unclear. A strong relationship has been reported in patients having undergone liver transplantation. Low serum vitamin D 25 levels have been correlated with osteoporosis post liver transplantation 29 . However, after the fi rst four months post liver transplantation, bone mass increased and higher serum vitamin D 25 levels were found 30 . Vitamin D defi ciency has recently been associated with high activity grade and stage of liver fi brosis in patients with chronic viral hepatitis C; in addition, vitamin D defi ciency seems to be a risk factor in patients with no sustained virologic response when treated with peginterferon and ribavirin 31 . In the study by Duarte et al., serum calcium was lower in patients with cirrhosis than non-cirrhotic ones; there was no proven connection between vitamin D defi ciency and bone loss in chronic viral hepatitis 32 . Verma et al. found that patients with primary biliary cirrhosis presented low spinal and femoral neck BMD and reduced fractional calcium absorption. However, additional studies are necessary to confi rm that an increase in fractional calcium absorption may result in increased bone strength in patients with primary biliary cirrhosis 33 .
Vitamin K defi ciency
Vitamin K has an important role in the production of the bone matrix protein osteocalcin (a protein produced by osteoblast cells). Data have shown that in primary biliary cirrhosis, bone disorders were caused by vitamin K defi ciency and that supplementation of vitamin K may prevent bone loss 34 .
Insulin-like 1 growth factor defi ciency
Osteoblasts and liver produce IGF-1, which is lower in the elderly and CLD patients. Th ere are studies suggesting that low levels of IGF-1 may cause bone disorders, especially in CLD with cholestasis 4, 12 .
Hyperbilirubinemia
High bilirubin levels are often found in CLD, although the sequels of chronic cholestasis on bone tissue have not yet been established. Ruiz-Gaspa et al. studied the eff ects of bilirubin and serum from patients with jaundice on bone cells. Th ey have reported that unconjugated bilirubin and serum from these patients aff ect osteoblast function and cause decreased bone formation, thus possibly contributing to the pathogenesis of HO 35 .
Sex hormone defi ciency
Normal bone metabolism requires normal sex hormone balance. In cirrhotic postmenopausal women, low levels of luteinizing hormone, follicle-stimulating hormone and estradiol, but normal testosterone levels were found 36 . Defi ciency of testosterone is a common factor for bone disorders in men with CLD, especially when liver disease is severe (end stage liver disease) and it is an independent predictor of mortality 37, 38 .
Receptor activator of nuclear factor kappa B ligand/osteoprotegerin (RANKL/OPG) system
Inadequate activity of the RANKL/OPG system has been reported. Th is system includes cytokines that modulate osteoclast activity, since parathyroid hormone (PTH) does not have receptors on this type of cells. Usually, this system works as activating osteoclasts by RANKL (increasing bone resorption) and inhibiting osteoclast activity by osteoprotegerin; osteoprotegerin binds RANKL so that its activating power is stopped (decreasing bone resorption). Th us, any imbalance of this system such as increasing RANKL activity or decreasing osteoprotegerin activity leads to bone disorders (loss of bone mass) 39 . Th is hypothesis is not yet clearly defi ned. In their study, Gaudio et al. did not confi rm the fact that RANKL/ OPG system could have a role in HO pathogenesis and they suggest that the increasing levels of osteoprotegerin may represent not only compensation for bone resorption but also a result of the infl ammatory process in CLD 38 . Interleukin-6, a cytokine synthesized by osteoblasts, is an osteoclast activating factor. It may also stimulate osteoblasts to produce RANKL and thus promote bone resorption 40 . Th ere are studies which suggest that blockade of IL-6 receptor may lead to inhibition of the osteoclasts both in vitro and in vivo 5 .
Drugs
Glucocorticoid therapy may lead to drug-induced osteoporosis. Th e usage of glucocorticoids in CLD treatment (autoimmune and chronic cholestatic liver diseases) may accelerate development of osteoporosis. Glucocorticoids alter the balance between osteoclast and osteoblast activity in mineral bone metabolism (induce osteoblast apoptosis and prolong the lifespan of osteoclasts) 41, 42 . Other drugs have been reported to interfere with calcium absorption, e.g., diuretics, antibiotics, and non-steroidal anti-infl ammatory drugs 43 . Th e use of benzodiazepine drugs has been found to correlate with fragility fractures in women 26 . Cholestyramine is also a drug that may interfere with bone metabolism because of the adverse eff ect on the intestinal vitamin D absorption 4 . Regarding antiviral therapy little is known about the eff ect of the combination of ribavirin plus interferon (IFN) on BMD in patients with chronic hepatitis C, but back pain and bone fractures have been reported 44 . Hofmann et al. have reported that BMD increased in patients administered pegylated interferon α and ribavirin, especially in those having achieved sustained virologic response 45 . In their study, SolisHerruzo et al. concluded that in patients with chronic hepatitis C the IFN-α and ribavirin therapy for 12 months could induce bone loss in almost all patients 46 . Redondo-Cerezo et al. have reported recently that bone mass improved in hepatitis C patients who responded to antiviral therapy with ribavirin and pegylated IFN-α 47 . Th e reduction of BMD in hepatitis B patients who received nucleoside (telbivudine, entecavir) and nucleotide (adefovir, tenofovir) analogs has also been studied but there are controversies. In a study of 319 chronic hepatitis B patients, the parameters such as age, gender, and nucleoside and nucleotide analog therapy correlated independently with bone loss 48 . Buti et al. have recently shown data on longterm tenofovir disoproxil fumarate treatment in chronic hepatitis B infection, and no signifi cant change in BMD was noticed in 7 years of the study 49 . In another study, the prevalence of bone loss in chronic hepatitis B was similar in patients that were not treated with tenofovir and in those having received tenofovir for 12 months 50 . Still, evaluation of BMD should be performed in patients receiving prolonged tenofovir treatment 51 . Data are also limited about adefovir dipivoxil but lately many cases of osteomalacia due to adefovir treatment have been reported. Tanaka tis B infection for 5 years and underwent total hip arthroplasty for osteomalacia and pathological hip fracture probably due to this treatment 52 . Reduced BMD may be partially caused by CLD per se; also, low BMD may have existed prior to the introduction of antiviral therapy.
Other factors
Tumor necrosis factor (TNF) stimulates bone resorption and may cause bone disorders in patients with CLD 53 . Elevated levels of soluble TNF receptor (sTN-FR-55) may also have a role in the pathogenesis of HO 47 . Another factor involved in the pathophysiology of osteoporosis in CLD is leptin, a cytokine produced by adipocytes. Leptin plays a role both in hunger/satiety mechanisms and in bone metabolism. Th ere is a hypothalamic central mechanism of leptin with anti-osteoporotic activity and also a peripheral leptin mechanism of increasing osteoblast proliferation, stimulating bone matrix synthesis and inhibiting RANKL activity 54, 55 . Data suggest that leptin levels are associated with BMD loss, especially in patients with primary biliary cirrhosis 56 . Piche et al. have reported that high leptin levels are found in patients with chronic hepatitis C and these are correlated with the severity of liver fi brosis 57 . In addition, it has been reported that there is an inverse association between serum leptin levels and BMD in patients with advanced liver disease 58 . Pacifi co et al. investigated the relationship between BMD and serum adipokines and high sensitivity C reactive protein levels in patients with nonalcoholic fatty liver disease, and found that low grade of systemic infl ammation may decrease BMD (high sensitivity protein C was an independent factor associated with bone loss and low Z scores at lumbar spine) 59 . Fibronectin is also a factor involved in bone metabolism. Fibronectin is a protein produced by a variety of cell types including cells of bone and liver. Fibronectin produced by liver goes to blood stream and its concentration is low in malnutrition and severe liver disease. Th e circulating isoform of fi bronectin provided by the liver infi ltrates the matrix of bone and increases matrix mineralization without aff ecting bone function and number of bone cells 60 . An isoform of fi bronectin named oncofetal fi bronectin has been found in high levels in patients with primary biliary cirrhosis and it mediates bone loss by inhibiting bone formation 61 . Homocysteine is also a player implicated in bone remodeling by increasing osteoclast activity, decreasing osteoblast activity, and it also has a direct eff ect on the bone matrix 62 . Hyperhomocysteinemia has been reported to be associated with low BMD as an independent risk factor for osteoporosis and osteoporotic fractures 63 . High levels of homocysteine have been found in patients with viral hepatitis C and can be reduced to normal range by standard antiviral therapy with IFN-α and ribavirin 64 .
Lifestyle factors
In the pathogenesis of bone disorders due to CLD, behavioral factors such as alcoholism, cigarette smoking, malnutrition, low body mass index (BMI) and sedentary lifestyle have also been studied. Alcohol is an independent risk factor for osteoporosis; the hip fracture risk is 2.8 times higher than normal in alcoholic individuals 1 . Kim et al. have reported that chronic alcohol consumption leads to low BMD in the femur Ward's triangle and trochanter 65 . Cigarette smoking is also a risk factor that may be associated with osteoporosis in CLD 16, 18, 20, 66 . In postmenopausal women who have never smoked, passive smoking has been correlated with osteoporosis; also, the severity of lumbar and femoral neck osteoporosis has been positively associated with the number of cigarettes smoked by cohabitant smokers 67 . Low BMI and malnutrition encountered in alcoholics are associated with bone loss, especially in those that have irregular feeding habits 68 . Low BMI has been found to be associated with low BMD in patients with CLD 16, 18, 66 . In the study by Pinheiro et al., 2420 individuals were investigated and sedentary lifestyle was found in women as a risk factor, along with age, family history of hip fracture, early menopause, poor quality of life, diabetes mellitus, use of benzodiazepine drugs, and recurrent falls. In the same study, the risk factors for osteoporosis in men were sedentary lifestyle, current smoking, poor quality of life, and diabetes mellitus 26 .
Diagnosis of Hepatic Osteodystrophy
Osteoporosis is a systemic bone disease consisting of low bone mass and micro architectural disorders of bone tissue which leads to bone fragility and bone fractures (fragility fractures) 69 . Th e gold standard in the diagnosis of HO is assessment of BMD by using DXA at lumbar vertebrae and femoral neck 70 . According to the World Health Organization (WHO), osteoporosis is defi ned as T-score less than -2.5 (BMD less than 2.5 standard deviations compared to normal average score of young adults); osteopenia is defi ned as T-score between -1 and -2.5 70 . In individuals less than 50 years of age, the Z-score is used, which represents BMD of patient compared to mean BMD of age-, race-and sex-matched controls 71 . Th ese ranges refer only to BMD decrease, but there are many individual factors that should be assessed. Because of the individual risk, WHO has developed the Fracture Risk Assessment Tool (FRAX®), an instrument which takes into consideration many individual factors such as clinical factors and BMD at femoral neck. FRAX calculates the probability of hip fracture in ten years and the probability of major osteoporotic fracture (vertebral fractures, hip, humerus, forearm) in ten years 72, 73 . In 2002, Collier et al. published guidelines for osteoporosis management in patients with CLD 1 . Strong risk factors for osteoporosis require systematic BMD measurements and optimal treatment for prevention of fragility fractures, both in the absence and presence of CLD (associated with one or more risk factors) in every patient (Table 3) 1,6 . Additionally, fragility fractures indicate severe osteoporosis and patients need immediate treatment without BMD scan 1 . In 2003, the American Gastroenterological Association (AGA) published guidelines for osteoporosis in liver and gastrointestinal disease 74 . AGA recommends that vitamin D levels and BMD be assessed in all cirrhotic patients. Patients who have a history of personal fragility fracture, postmenopausal women and patients with long-term glucocorticoid therapy (>3 months) should have BMD evaluation. BMD measurement should also be performed in patients with primary biliary cirrhosis, cirrhosis, and patients undergoing liver transplantation. Patients who have risk factors and normal initial BMD test should be assessed after 2-3 years in order to exclude signifi cant bone loss. A shorter interval for reevaluation of BMD (1 year) is recommended for patients on glucocorticoid therapy initiated recently and in high doses. In patients diagnosed with osteoporosis who have both elevated γ-glutamyltransferase and serum alkaline phosphatase levels, screening for anti-mitochondrial antibodies should be performed because of the underlying cholestatic liver disease (which may have osteoporosis as the fi rst clinical manifestation).
Th e 2003 World Gastroenterology Organization (WGO) Practice Guidelines for osteoporosis in gastrointestinal diseases recommend that repeated DXA scans should be performed at 12-to 18-month intervals 6 . In addition, WGO recommends that fracture risk be assessed individually and decision should be made 'patient-by-patient'. If DXA scan is not available, patients at a high risk may be treated empirically 6 . Considering the high prevalence of HO, every patient with CLD should have complete evaluation of bone mass by detecting vitamin D and blood calcium levels, measuring BMD by DXA, besides using FRAX. Th e thyroid and gonadal functions should also be evaluated in patients to exclude other forms of osteoporosis (Table 4) .
Vitamin D blood level should be determined in HO patients, especially those with possible low levels, for example, those receiving glucocorticoids.
Blood calcium level should be determined in patients with HO in order to exclude other causes of secondary endocrine osteoporosis. Evaluating the risk of osteoporosis at least once in the evolution of CLD should be considered 23 . Patients with T-score less than -2.5 need immediate anti-osteoporotic treatment. De- 1, 6 History of premature maternal hip fracture (<60 years) Hypogonadism (primary hypogonadism, early menopause (age <45 years), secondary amenorrhea >6 months) 5 mg prednisolone (or equivalent)/day (≥3 months) Osteopenia evidenced by x-ray scan Height loss >4 cm Low body mass index (<19 kg/m 2 ) tection of T-score values between -1 and -2.5 indicates osteopenia and supplementation of calcium and vitamin D intake is required. In cirrhotic patients with ascites, paracentesis should be performed fi rst, followed by BMD measurements because it has been demonstrated that fl uid may erroneously reduce BMD values at lumbar spine during DXA scan 23, 75, 76 . In patients with bone disorders, bone turnover markers may also be detected; they are products of the bone remodeling process found in the blood and urine of these patients. Th e most widely used osteogenesis markers are osteocalcin, alkaline phosphatase (bone isoenzyme), procollagen type 1 carboxyterminal propeptide, and procollagen type 1 aminoterminal propeptide. Resorption markers are urinary pyridinoline, deoxypyridinoline, type 1 collagen amino-terminal telopeptide, and hidroxyprolinuria. All these markers are expressed related to urinary creatinine. Th ere is little information in studies about bone turnover markers. In the study by Yenice et al., higher levels of urinary telopeptide were reported in postmenopausal women with chronic hepatitis B than in other groups 77 . Schiefke et al. found elevated levels of alkaline phosphatase (bone isoenzyme) to be associated with histologically proven advanced viral chronic hepatitis 9 . So far, there is no consensus regarding their use in clinical practice in CLD patients 1,2,13,77 .
Management of Hepatic Osteodystrophy
Data on the management of patients with HO are insuffi cient and the best algorithm for diagnosis and treatment of patients with HO is individual management of every patient with CLD 1, 74 . According to the AGA, the management of osteoporosis in liver disease refers to three categories of patients who need BMD measurements using DXA: patients with CLD plus any of risk factors; patients with CLD undergoing liver transplantation; and patients with CLD and vertebral compression fractures in whom DXA scan is optional at baseline but treatment is mandatory 74 .
• For patients with normal T-score (T-score >-1), general prevention measures are recommended; for patients receiving long-term corticosteroid treatment and having normal T-score on DXA scan, both general measures and BMD reevaluation by DXA in one year are necessary.
• For osteopenia (T-score between -1 and -2.5), patients should follow general prevention measures and repeat DXA scan in two years; in patients with long-term glucocorticoid therapy and osteopenia, bisphosphonates should be considered and DXA scan performed in one year. • Finally, for osteoporotic patients (T-score <-2.5), the recommendations are: general prevention measures, screening for other causes of osteoporosis and considering bisphosphonate therapy, otherwise they should be referred to a bone specialist.
Treatment of Hepatic Osteodystrophy
Treatment of HO patients includes general prevention measures and specifi c anti-osteoporotic therapy.
General prevention measures
Lifestyle measures involve reducing alcohol consumption, stopping smoking, having regular moderate physical exercise, and avoid falls 1, 2 . It is also recommended to limit the use of drugs such as diuretics, glucocorticoids and cholestyramine 78 . Dietary measures refer to appropriate nutrition to avoid malnutrition and low BMI as risk factors for osteoporosis; dietary supplementation of calcium and vitamin D is recommended. Th e National Osteoporosis Foundation has established that adequate calcium intake is 1200 mg/ day or more and vitamin D intake 800 -1000 IU/day; the optimal blood level of 25-hydroxyvitamin D is approximately 30-60 ng/mL 79 . 84 .
Specifi c anti-osteoporotic therapy
Th e agents used in osteoporosis treatment so far are hormone replacement therapy (HRT), selective estrogen receptor modulators, bisphosphonates, calcitonin, parathyroid hormone, and a combination of diff erent therapies. Th e WGO recommends that if these drugs are not available for any reason, then vitamin D intake and sun exposure should be increased; the possibility to add vitamins in the food has also been discussed 6 . Currently, using HRT in HO treatment remains controversial. HRT with estrogens and progesterone is indicated as sequential or continuous combination therapy in women with liver disease and it can be administered orally or transdermally 1, 85 . Th is treatment should be used with caution because of its potential long-term risk to develop breast, gallbladder, endometrium or bladder cancers; however, HRT may have a protective eff ect against colorectal and liver cancers 6, 86 . HRT with testosterone in men without liver disease increased BMD 87 . Th ere are reports on the safety of these drugs in patients with liver disease 85 . Th ese drugs increased BMD by 5% and reduced the risk of fracture by 50% 6 . Th e impact of HRT on BMD and fracture rate in postmenopausal or hypogonadal women with CLD was investigated in small studies 1 . In patients with primary biliary cirrhosis, HRT improved lumbar spine BMD without impairing cholestasis 88 . Selective estrogen receptor modulators have benefi cial eff ects on BMD at lumbar spine and femoral neck, and decrease vertebral fracture risk in postmenopausal women 2 . Raloxifene improved BMD in osteopenic women with primary biliary cirrhosis 89 . Also, raloxifene proved to be an adjuvant in standard treatment with pegylated IFNα2a and ribavirin in postmenopausal women with chronic hepatitis C 90 . Bisphosphonates are the most widely used drugs in postmenopausal osteoporosis reducing the rate of vertebral/hip fractures and height loss. Th ey are antiresorptive agents that inhibit osteoclast activity and thus stop bone loss 91 . Th ey are also used in preventing glucocorticoid induced osteoporosis. In the study by Yurci et al., patients with chronic viral hepatitis and cirrhosis who had reduced DXA T-scores were treated for one year with diff erent therapeutic regimens; three groups of patients were treated with alendronate 10 mg, alendronate 70 mg and risendronate 5 mg, respectively. Tscores improved signifi cantly in all regions with alendronate 70 mg, and at lumbar spine and distal radius regions with alendronate 10 mg and risendronate 5 mg 83 . Wolfhagen et al. have reported that cyclic etidronate seems to prevent osteoporosis induced by prednisone treatment in patients with primary biliary cirrhosis 92 . Cyclic etidronate has also been reported to reduce the incidence of bone fractures in postmenopausal women with chronic hepatitis B and C
93
. Pennisi et al. have suggested that pamidronate treatment decreases bone turnover and prevents bone loss after liver transplantation but the eff ect on bone at 12-month followup is limited to trabecular bone and not to cortical bone of the femur 94 . In patients with primary biliary cirrhosis, alendronate has better antiresorptive eff ect than etidronate 95 . Oral administration of alendronate should be avoided because of the risk of ulceration in esophageal mucosa (especially in cirrhosis patients with esophageal varices in whom variceal hemorrhage may appear). In contrast, risendronate has not been reported to have adverse eff ect on esophageal mucosa 1, 96 . Additionally, in another study, there were no adverse eff ects, including variceal hemorrhage 83 . Zolendronic acid, another bisphosphonate, has been investigated in the last years and was found to prevent bone loss and reduce bone turnover and fractures in the fi rst year after liver transplantation 97, 98 . Currently, bisphosphonates are the most frequently used drugs for the treatment of HO, however, there is little information about their usage in liver diseases 74, 78 . Th ey have been labeled as safe and most effi cient ones, not only in preventing cortical bone loss but also in preventing trabecular bone loss, especially in chronic viral liver disease 83 . Calcitonin decreases bone loss and vertebral fracture rate in osteoporosis of postmenopausal women tients with chronic viral hepatitis and cirrhosis who had reduced T-scores at DXA were treated with diff erent therapeutic regimens; one patient group was treated with calcitonin 200 IU and their T-scores improved signifi cantly in the lumbar spine region after one-year treatment 83 . In patients with primary biliary cirrhosis, parenteral calcitonin administration had no eff ective results on bone loss when administered for 6 months 100 . Additionally, 6-month calcitonin therapy had no eff ect on preventing or reducing bone loss or fractures occurring in the fi rst year of liver transplantation in patients with primary biliary cirrhosis and primary sclerosing cholangitis 101 . So far, this drug has been tested in a small number of studies and it remains as second line therapy after bisphosphonates.
Parathyroid hormone as a human recombinant form may be used to treat osteoporosis. It is administered subcutaneously and has been approved for the treatment of postmenopausal osteoporosis 74 . PTH administration is very expensive and it is used in severe cases of osteoporosis (T-score < -3.5) 6 . Recently, Leder et al. studied a novel synthetic peptide analog of PTH related protein named abaloparatide in postmenopausal women with osteoporosis. Th ey concluded that abaloparatide increased BMD at lumbar spine, femoral neck and total hip in a dose dependent manner 102 . Th ere is little information about using PTH in osteoporosis due to liver disease. Recently, Anagnostis et al. have published a case of a liver transplant patient with severe osteoporosis who developed de novo autoimmune hepatitis after administration of PTH and PTH 103 .
Conclusions
Hepatic osteodystrophy is a common complication in patients with CLD, which has attracted attention of many researchers from this fi eld in the last years. Th is pathology involves osteoporosis or osteopenia, and sometimes osteomalacia, and may lead to morbidity (bone pain, skeletal deformities, immobilization, and fragility fractures) which aff ects the quality of life and survival. Th ere are many factors that have been reported in the etiology of HO but the pathogenesis of this type of osteoporosis is still incompletely understood. Bone loss should be assessed in all patients with CLD. Th e management of bone disorders in CLD has not yet been established because of the lack of large therapeutic interventional trials in this fi eld. Th erefore, it is mandatory that the researchers keep their focus on HO in order to defi ne better the pathogenesis, management of fracture risk, and treatment of this complication of CLD. 
